KE Holdings Inc vs Quest Diagnostics Inc — how do they compare? KE Holdings Inc trades at $17.45 (market cap $18.92B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and KE Holdings Inc pays the higher dividend (1.63%). Which is the better fit depends on your goals.
| BEKE | DGX | |
|---|---|---|
Market Cap | $18.92B | $26.21B |
Sector | Technology | Health |
52-Week High | $20.36 | $238.50 |
52-Week Low | $14.26 | $173.49 |
Enterprise Value | $14.66B | $31.97B |
Dividend Yield | 1.63% | 1.45% |
Signals from Pluang's Aura AI — not financial advice
BEKE trades at $17.42, down 1.3% today but showing technical bullish signals with strong analyst support. The company reported mixed quarterly results with a Q1 2026 earnings beat but missed Q4 2025 expectations. Revenue declined from $94.6B in 2025 to $90.1B projected for 2026, though net profit margin improved to 3.76%. Technical indicators show bullish momentum with ADX signals supporting upward trend potential.
Outlook remains positive with 92% analyst buy ratings, though investors face risks from China's property market volatility and recent revenue contraction. The stock's valuation at P/E 38.5 appears elevated relative to growth, requiring sustained earnings improvement to justify current multiples. Cash flow trends show improvement with operating cash flow turning positive in 2026 projections.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Trailing returns across standard periods
Latest headlines on both assets
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →